284 related articles for article (PubMed ID: 32744901)
1. Auditory Cinchonism in COVID Era.
Saniasiaya J; Kulasegarah J
Ear Nose Throat J; 2020 Nov; 99(9):597-598. PubMed ID: 32744901
[No Abstract] [Full Text] [Related]
2. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN
CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
[No Abstract] [Full Text] [Related]
3. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
[No Abstract] [Full Text] [Related]
4. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
5. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.
Cairoli E; Espinosa G
Med Clin (Barc); 2020 Aug; 155(3):134-135. PubMed ID: 32425245
[No Abstract] [Full Text] [Related]
6. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
7. Hydroxychloroquine in Covid-19: Does the end justify the means?
Yakoub-Agha I
Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
[No Abstract] [Full Text] [Related]
8. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
9. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Roden DM; Harrington RA; Poppas A; Russo AM
Circulation; 2020 Jun; 141(24):e906-e907. PubMed ID: 32267732
[No Abstract] [Full Text] [Related]
10. Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.
Rani S; Grover S; Mehra A; Sahoo S
Indian J Pharmacol; 2020; 52(3):229-231. PubMed ID: 32874009
[No Abstract] [Full Text] [Related]
11. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
12. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Machiels JD; Bleeker-Rovers CP; Ter Heine R; Rahamat-Langendoen J; de Mast Q; Ten Oever J; Bousema T; van Crevel R; Wertheim HF
Int J Antimicrob Agents; 2020 Jul; 56(1):106056. PubMed ID: 32674929
[TBL] [Abstract][Full Text] [Related]
13. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.
Chang D; Saleh M; Gabriels J; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Epstein LM
J Am Coll Cardiol; 2020 Jun; 75(23):2992-2993. PubMed ID: 32330546
[No Abstract] [Full Text] [Related]
14. Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!
Ciorba A; Corazzi V; Skarżyński PH; Skarżyńska MB; Bianchini C; Pelucchi S; Hatzopoulos S
Int J Immunopathol Pharmacol; 2020; 34():2058738420941754. PubMed ID: 32649262
[TBL] [Abstract][Full Text] [Related]
15. Searching for COVID-19 treatments: First, do no harm.
Guharoy R; Krenzelok E
Am J Health Syst Pharm; 2020 Oct; 77(22):1899-1905. PubMed ID: 32744592
[No Abstract] [Full Text] [Related]
16. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E
J Glob Antimicrob Resist; 2020 Sep; 22():842-844. PubMed ID: 32763357
[TBL] [Abstract][Full Text] [Related]
17. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Habibzadeh P; Moghadami M; Lankarani KB
Med Hypotheses; 2020 Oct; 143():109847. PubMed ID: 32460209
[No Abstract] [Full Text] [Related]
18. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
Voisin O; Lorc'h EL; Mahé A; Azria P; Borie MF; Hubert S; Ménage E; Guillerm JC; Mourad JJ
Mayo Clin Proc; 2020 Aug; 95(8):1696-1700. PubMed ID: 32753141
[TBL] [Abstract][Full Text] [Related]
19. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
Grandolfo M; Romita P; Bonamonte D; Cazzato G; Hansel K; Stingeni L; Conforti C; Giuffrida R; Foti C
Dermatol Ther; 2020 Jul; 33(4):e13499. PubMed ID: 32362051
[No Abstract] [Full Text] [Related]
20. Covid-19 treatment update: follow the scientific evidence.
Becker RC
J Thromb Thrombolysis; 2020 Jul; 50(1):43-53. PubMed ID: 32338320
[No Abstract] [Full Text] [Related]
[Next] [New Search]
